Summary:
In this issue, Dietrich, Trub, and colleagues describe and characterize a novel selective CDK2 inhibitor: INX-315. This agent shows promise in CCNE1-amplified cancers and in CDK4/6 inhibitor–resistant breast cancers.
©2024 American Association for Cancer Research
2024
American Association for Cancer Research
You do not currently have access to this content.